Week In Review: Seattle-Suzhou ADC Biotech ProfoundBio Acquired By Genmab For $1 8 Billion seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Qitan Technology completed a $101 million Series C round to support its commercialized nanopore devices. Takeda was approved to launch Exkivity (mobocertinib) in China.
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
News provided by
Share this article
Share this article
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathyroid hormone).
2. PaTHway China Trial is designed to assess the potential of TransCon™ PTH as a hormone replacement therapy, and the aim is to enable patients to have serum calcium (sCa) within the normal range and independence from usual care.
Introducing Finley, the fintech newsbot from China Money Network!
Using state-of-the-art machine learning technologies, Finley scours the globe for immediately usable data about the latest private equity deals, venture capital funding rounds, and business expansions happening in China.
Finley asks: Who s buying whom? What company just raised new capital? What is the relationship among the parties?
Then Finley uses his very real artificial intelligence to decipher that unstructured data to write news articles for you to read.
So from unstructured data to a news story you can understand, China Money Network s Finley is your fintech newsbot business partner!
RELATED NEWS